Prediction of morbidity and mortality in patients with chronic hepatitis C by non-invasive liver fibrosis models

Liver International

Volumn 34, Issue 5, 2014, Pages 720-727

  Chinnaratha, Mohamed A ^a   Jeffrey, Gary P ^a,b   Macquillan, Gerry ^a,b   Rossi, Enrico ^c   de Boer, Bastiaan W ^c   Speers, David J ^b,c   Adams, Leon A ^a,b  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

Hepascore; Non invasive markers; Prognosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HYALURONIC ACID; INTERFERON; PEGINTERFERON; RIBAVIRIN; BIOLOGICAL MARKER;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX; BILIRUBIN BLOOD LEVEL; CAUSE OF DEATH; COHORT ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; FEMALE; FIB 4; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPASCORE; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; MORTALITY; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; AUSTRALIA; BIOPSY; BLOOD; CARCINOMA, HEPATOCELLULAR; COMPLICATION; EPIDEMIOLOGY; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; VIROLOGY;

ADULT; BIOLOGICAL MARKERS; BIOPSY; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; WESTERN AUSTRALIA;

EID: 84897965641     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12306     Document Type: Article

References (31)

1. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-14.
2. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231-64; quiz 214-7.
3. Hatzakis A, Wait S, Bruix J, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat 2011; 18 (Suppl 1): 1-16.
4. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36(5 Suppl 1): S35-46.
5. Serfaty L, Aumaître H, Chazouillères O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27: 1435-40.
6. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26(3 Suppl 1): 34S-8S.
7. Walter SR, Thein HH, Amin J, et al. Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. J Hepatol 2011; 54: 879-86.
8. Neal KR, Trent Hepatitis C Study Group, Ramsay S, Thomson BJ, Irving WL. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 2007; 56: 1098-104.
9. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
10. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36(5 Suppl 1: S47-56.
11. Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97-104.
12. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-8.
13. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500.
14. Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867-73.
15. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006 43: 1317-25.
16. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
17. Holman CD, Bass AJ, Rouse IL, Hobbs MS. Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 1999; 23: 453-9.
18. Ives A, Saunders C, Bulsara M, Semmens J. Pregnancy after breast cancer: population based study. BMJ 2007; 334: 194.
19. Zhang M, Holman CD, Price SD, et al., Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study. BMJ 2009; 338: a2752.
20. Knuiman MW, Welborn TA, Whittall DE. An analysis of excess mortality rates for persons with non-insulin-dependent diabetes mellitus in Western Australia using the Cox proportional hazards regression model. Am J Epidemiol 1992; 135: 638-48.
21. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20(1 Pt 1): 15-20.
22. Gellad ZF, Reed SD, Muir AJ. Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C. Antivir Ther 2012; 17(6 Pt B): 1189-99.
23. Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52: 652-7.
24. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-87.
25. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930-8.
26. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687-95.
27. Ngo Y, Munteanu M, Messous D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006; 52: 1887-96.
28. Nunes D, Fleming C, Offner G, et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 2010; 105: 1346-53.
29. Guéchot J, Serfaty L, Bonnand AM, et al. Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. J Hepatol 2000; 32: 447-52.
30. Vergniol J, Foucher J, Terrebonne E, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140: 1970-9, 1979 e1-3.
31. Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59: 1245-51.